|
Recent Developments |
|
17-DEC-18
Biocon announced that the USFDA conducted a GMP inspection of its API manufacturing facility at Telangana from December 12, 2018 to December 14, 2018. The inspection concluded without any observations and no Form 483 was issued.
12-NOV-18
Biocon announced that the U.S. FDA conducted a pre approval inspection of the company's new Oral Solid Dosage Forms manufacturing facility at Biocon Park, Bengaluru from November 05 to November 09, ... More.. |
| Business Profile |
Future Plans |
|
|
|
|
One To One
|
|
Recent news
|
|
|
| Brief Financials (in Rs. Mn.) | |
| Period ending (months) | 31-Dec-2017(9) | 31-Mar-2017 (12) | 31-Mar-2016(12) | | Net sales | 17774.00 | 26184.00 | 21611.10 | | Other Income | 1092.00 | 988.00 | 1840.90 | | Total Income | 18866.00 | 27172.00 | 23452.00 | | Cost of goods sold | 15636.00 | 21810.00 | 18842.30 | | OPBDIT | 3230.00 | 5362.00 | 4609.70 | | PAT | 1666.00 | 5193.00 | 8087.70 | | Gross Block | - | - | - | | Equity capital | - | 0.00 | 1000.00 | | EPS (Rs.) | - | 0.00 | - | | DPS (Rs.) | - | - | - | | BV (Rs.) | - | - | - | | P/E range (x) | - | NA | - | | Debt / Equity (x) | - | - | - | | Operating margin (% of OI) | 17.1 | 19.7 | 19.7 | | Net margin (% of OI) | 8.8 | 19.1 | 34.5 |
|
|
Detailed Financials
|
|
|
|
|
